Overview
How can artificial intelligence (AI) and advanced data technologies revolutionize the future of life science clinical development? In an era where clinical trials require more efficient and streamlined processes to reduce complexity and enhance accuracy, AI is well-positioned to make a significant impact. Join us on 5 December 2024 for an engaging session that explores these intricacies by bringing together representatives from Johnson & Johnson, industry leaders, and oncology experts!
Attendees can look forward to gaining insights into the latest innovations reshaping the clinical trial landscape—with a focus on oncology—from identifying targeted patient populations to optimizing trial design and execution. We will also examine the integration of real-world data (RWD) and real-world evidence (RWE) in clinical studies, demonstrating how these resources are vital for refining trial methodologies and expediting regulatory approvals. Our expert panel will present compelling case studies showcasing innovative applications of AI and data technologies that have improved recruitment strategies, streamlined protocols, and tackled common challenges in clinical research.
Join us for a forward-thinking dialogue on the future of life science research, underscoring the imperative for continued adaptation and innovation in a rapidly evolving field.
As capacity is limited, please register for the waitlist. You'll receive an email if your spot is confirmed. Thank you for your patience and understanding!
Photography and videography will be captured during this event. Through your participation, you are granting Johnson & Johnson Innovation - JLABS consent to utilize these images and videos for promotional purposes, which may include social media, website and publication purposes. If you do not wish to be photographed, kindly inform the photographer at the event.
Schedule
Date: 05 Dec 2024, Thursday
Time: 3:30 PM - 6:30 PM (GMT +8:00) Kuala Lumpur, Singapore
Location: Guoco Midtown Network Hub, 126 Beach Road, Singapore, 189772
Speakers
Moderator's Profile:
James Gallagher, Head, Early Innovation – Innovative Health, Global Development, Johnson & Johnson Innovative Medicine
James is a seasoned leader and innovator in global drug development, currently serving as the head of early innovation within Innovative Health. In this role, he leads multiple teams focused on discovering and delivering transformative capabilities to revolutionize Global Drug Development. His responsibilities also include overseeing externally funded projects and managing large consortia that drive impactful collaboration. In 2024, James also served as the global head of patient and site engagement, spearheading the creation of a new site engagement strategy. With over 20 years of experience in biometrics, clinical innovation, and business transformation, James joined from Novartis, where he held pivotal roles as global head of statistical programming and platform/strategy head for clinical technology and innovation.
Speaker's Profile:
Adj A/Prof. Danny Soon, CEO, Consortium for Clinical Research and Innovation Singapore (CRIS)
Adj A/Prof Danny Soon is Chief Executive Officer of the Consortium for Clinical Research and Innovation Singapore (CRIS), concurrent Executive Director of the Singapore Clinical Research Institute (SCRI) and the Interim Executive Director of Advanced Cell Therapy and Research Institute, Singapore (ACTRIS). As the inaugural CEO of CRIS, Adj A/Prof Soon oversees team building and operations to bring together key national translational research programmes, to forge greater synergies and impact for healthcare and economic value. At SCRI, his team has a key role in supporting clinical trials for academic researchers, growing research networks, and growing talent in clinical research. At ACTRIS, he leads the team in implementing strategies for enhancing capabilities to meet the growing demand for cell therapy development and manufacturing for cancer treatments and regenerative medicine, so that Singapore can continue to be relevant in this fast-evolving biomedical field.
Speaker's Profile:
Sharon Chen, CEO and Co-Founder, AlphaLife Sciences
Sharon Chen, CEO and Co-Founder of AlphaLife Sciences, stands at the forefront of innovation where computer science meets life sciences. With over 25 years of exemplary software product development experience, she has consistently pushed the boundaries of technological advancement. In her previous roles, Sharon served as the Country General Manager at Verily Life Sciences, an Alphabet company, where she pioneered solutions integrating computer science with life sciences. As an Engineering Director at Google, she developed critical technological platforms and received prestigious accolades such as the "Founder's Award" and the "Outstanding Leadership Award" for her exceptional contributions and leadership. Sharon's unparalleled expertise in artificial intelligence, computer science, and life sciences uniquely positions her as a leading figure in the industry.
Speaker's Profile:
Dr. Huren Sivaraj, CEO and Co-Founder, Oncoshot
Dr. Huren Sivaraj, CEO of Oncoshot and breast cancer oncologist, has made significant contributions to oncology data solutions across APAC and, increasingly, within the UK and EU markets. His early work included creating a clinical-genomics database for breast cancer within SingHealth, which has since evolved into one of the region’s largest multiomics resources. At Oncoshot, Dr. Huren leads efforts in applying data federation systems, NLP, LLM and Robotic Process Automation (RPA) to enable secure, real-time data exchange among cancer centers. Oncoshot’s platform accelerates drug development, supports collaborative cancer research, and enhances patient care with trusted, data-driven insights across oncology.
Speaker's Profile:
Dr. Alessandro Falcone, Head, JLABS Singapore, Johnson & Johnson
As Head of JLABS Singapore, Dr. Alessandro Falcone is responsible for charting the strategic direction and overseeing all portfolio and business operational activities. Before assuming this role, Alessandro held the position of Executive Director in Oncology R&D at AstraZeneca, concentrating on the clinical development of the breast cancer portfolio. Prior to that, he occupied senior R&D and commercial positions at GSK and Novartis, respectively, over the past decade. At Novartis, he spearheaded European strategy and operations, while at GSK, he led technology and partnerships for all R&D endeavors. Alessandro's career also encompasses significant experience at top life science strategy consultancies such as LEK and IQVIA, with a particular focus on international investments in the life science sector. He holds an MD from UCL, and an M.Sc. with distinction in Experimental & Translational Therapeutics from the University of Oxford.
